Randomized Trialvery high evidence

Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).

The New England journal of medicine·November 7, 2026·PMID 43001734

Why it matters

Elevated lipoprotein(a) is an independent risk factor for cardiovascular events, and this trial tested whether potent lowering with an antisense oligonucleotide improves outcomes. The neutral result challenges the assumption that reducing lipoprotein(a) translates to clinical benefit, informing risk stratification and therapeutic expectations.

Infographic summary of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled